RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1250 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its Outperform rating for Regeneron Pharmaceuticals, maintaining a price target of $1250.
September 05, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Regeneron Pharmaceuticals, maintaining a price target of $1250.
The reiteration of an Outperform rating and a high price target by RBC Capital is a positive signal for Regeneron Pharmaceuticals, suggesting confidence in the company's future performance. This could lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100